FMS Launches multiFiltratePRO System for U.S. Patients With Acute AKI

Fresenius Medical Care launches multiFiltratePRO kidney therapy system in the United States, expanding critical care options and growth opportunities.

Zacks Investment Research • Oct 23, 2026

Fresenius Medical Care Brings Kidney Care Innovation to Critical Care Patients with U.S. Launch of multiFiltratePRO™

Expands access to Fresenius Medical Care's globally established portfolio of advanced kidney replacement therapies in the U.S. FDA clearance of multiFiltratePRO and approval of dedicated solutions expand continuous kidney replacement therapy options for U.S. patients requiring treatment for acute kidney injury Integrated technology helps hospital intensive care teams deliver complex treatment simply and efficiently BAD HOMBURG, Germany, Oct. 21, 2026 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for people with kidney disease, today announced the U.S. launch of the multiFiltratePRO System for critically ill patients with acute kidney injury (AKI). multiFiltratePRO's integrated technology eliminates the need for separate citrate and calcium pumps, and automatically adjusts as treatment conditions change, making complex treatment easier for hospital intensive care teams to manage.

PRNewsWire • Oct 21, 2026

Fresenius Medical Care presents new evidence and innovations advancing kidney care at ASN Kidney Week 2026

BAD HOMBURG, Germany, Oct. 19, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for people with kidney disease, presents new research and evidence-driven innovations aimed at improving patient outcomes during the American Society of Nephrology's (ASN) Kidney Week 2026, taking place October 21-25 in Denver, Colorado.

PRNewsWire • Oct 19, 2026

Reasons to Retain Fresenius Medical Stock in Your Portfolio for Now

FMS' transformation is lifting profitability, while HDF, value-based care and cost savings offset volume and reimbursement pressures.

Zacks Investment Research • Oct 7, 2026

Fresenius Medical Care Reshapes China Portfolio for Long-Term Growth

FMS refines its China strategy around advanced dialysis and critical-care technologies, with 110M euros in one-time costs.

Zacks Investment Research • Sep 29, 2026

Fresenius Medical Care Refines China Commercial Strategy with a Focus on Long-Term Growth and Market Leadership

Refinements support the Company's China go-to-market and commercial strategy in an important and growing market Strategy focuses on localized portfolio and innovation in China Portfolio decisions expected to result in related one-time costs in Q3 2026 treated as a special item BAD HOMBURG, Germany, Sept. 25, 2026 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today announced refinements to its China commercial strategy to support long-term growth and strengthen its market position through a more localized portfolio, increased commercialization of locally relevant innovation and a focused go-to-market approach.

PRNewsWire • Sep 25, 2026

Can Fresenius Medical's 5008X Rollout Drive the Next Growth Phase?

Fresenius Medical is scaling its 5008X rollout across U.S. clinics, creating growth potential despite volume, reimbursement and rollout-cost pressures.

Zacks Investment Research • Sep 3, 2026

3 Cheap International Stocks to Buy

These stocks have economic moats and look attractive today.

Morningstar • Aug 19, 2026

FMS Q2 Earnings Rise on Care Delivery, Revenues Miss, Margins Expand

FMS posts 28% EPS growth as Care Delivery profitability and margin gains offset a quarterly revenue miss and weaker US treatment volumes.

Zacks Investment Research • Aug 5, 2026

Dialysis firm FMC's shares slide despite earnings beat as US volumes disappoint again

Fresenius Medical Care shares fell in early trade on Tuesday, as investors looked past a second-quarter profit beat to ​focus on a fresh disappointment in U.S. patient volumes ‌and the management's decision to merely confirm, not raise, the full-year guidance.

Reuters • Aug 4, 2026